PT - JOURNAL ARTICLE AU - Laurence Don Wai Luu AU - Michael Payne AU - Xiaomei Zhang AU - Lijuan Luo AU - Ruiting Lan TI - Development and comparison of a novel multiple cross displacement amplification (MCDA) assay with other nucleic acid amplification methods for SARS-CoV-2 detection AID - 10.1101/2020.10.03.20206193 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.03.20206193 4099 - http://medrxiv.org/content/early/2020/10/06/2020.10.03.20206193.short 4100 - http://medrxiv.org/content/early/2020/10/06/2020.10.03.20206193.full AB - Objectives To develop a novel multiple cross displacement amplification (MCDA) assay for COVID-19 and compare its speed and sensitivity to existing loop-mediated isothermal amplification (LAMP) and real-time PCR (RT-PCR) methods.Methods Two MCDA assays targeting the SARS-CoV-2 N gene and ORF1ab was designed. The fastest time to detection and sensitivity of MCDA was compared to LAMP and RT-PCR using 7 DNA standards and transcribed RNA.Results For the N gene, MCDA was consistently faster than LAMP and RT-PCR by 10 and 20 minutes, respectively with a fastest time to detection of 5.2 minutes. RT-PCR had the highest sensitivity with a limit of detection of 100 copies/reaction compared with MCDA (1000 copies/reaction) and LAMP (5000/reaction). For ORF1ab, MCDA and LAMP had similar speed with fastest time to detection at 9.7 and 8.4 minutes, respectively. LAMP was more sensitive for ORF1ab detection with 500 copies/reaction compared to MCDA (5000 copies/reaction).Conclusions Different nucleic acid amplification methods provide different advantages. MCDA is the fastest nucleic acid amplification method for COVID-19 while RT-PCR is still the most sensitive. These advantages should be considered when determining the most suitable nucleic acid amplification methods for different applications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a UNSW school research grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research does not include clinical samples therefore no oversight approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the manuscript and/or in the supplementary materials.All data is provided in the manuscript and/or in the supplementary materials.All data is provided in the manuscript and/or in the supplementary materials.All data is provided in the manuscript and/or in the supplementary materials.